| Literature DB >> 23035960 |
Michael Owusu1, Samuel Blay Nguah, Yaw Agyekum Boaitey, Ernest Badu-Boateng, Abdul-Raman Abubakr, Robert Awuley Lartey, Yaw Adu-Sarkodie.
Abstract
BACKGROUND: Meningitis is an important cause of morbidity and mortality in low-resource settings. In sub-Saharan Africa, the meningitis belt has been characterized by particularly high and seasonal incidences of bacterial meningitis extending throughout life. Despite the progress being made in treating the condition, the mortality rates continue to be high, ranging between 2% and 30% globally. In Ghana, the mortality rate of meningitis has been estimated to range from 36% to 50%. However little information is available on the pathogens contributing to meningitis and their antimicrobial susceptibilities. Updated information is essential to adjust the recommendations for empirical treatment or prevention of meningitis which could have immense implications for local and global health.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23035960 PMCID: PMC3473245 DOI: 10.1186/1476-0711-11-28
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Yearly distribution of meningitis pathogens
| | ||||
| 0 | 2 (4.9) | 1 (3.2) | 3 (2.2) | |
| 53 (82.8) | 22 (53.7) | 16 (51.6) | 91 (66.9) | |
| 0 | 0 | 1(3.2) | 1 (0.7) | |
| 5 (7.8) | 6 (14.6) | 8 (25.8) | 19 (14.0) | |
| 0 | 0 | 1 (3.2) | 1 (0.7) | |
| 0 | 0 | 2 (6.5) | 2 (1.5) | |
| 2 (3.1) | 2 (4.9) | 0 | 4 (2.9) | |
| 1 (1.6) | 0 | 1 (3.2) | 2 (1.5) | |
| 0 | 3 (7.3) | 0 | 3 (2.2) | |
| 2 (3.1) | 2 (4.9) | 0 | 4 (2.9) | |
| 0 | 1 (2.4) | 0 | 1 (0.7) | |
| Coliforms | 0 | 2 (4.9) | 0 | 2 (1.5) |
| Coagulase negative staphylococcus. | 1 (1.6) | 1 (2.4) | 1 (3.2) | 3 (2.2) |
| Total | 64 (100.0) | 41 (100.0) | 31 (100.0) | 136 (100.0) |
Meningitis pathogens and age group distribution
| 1(6.7) | 0 | 1(3.4) | 1(2.0) | 0 | |
| 8(53.3) | 21(70.0) | 24(82.8) | 30(60.0) | 8 (66.7) | |
| 0 | 1(3.3) | 0 | 0 | 0 | |
| 1(6.7) | 3(10.0) | 0 | 0 | 0 | |
| 0 | 1(3.3) | 0 | 0 | 0 | |
| 2(13.3) | 0 | 0 | 0 | 0 | |
| 1(6.7) | 1(3.3) | 0 | 1 (2.0) | 1(8.3) | |
| 0 | 0 | 2(6.9) | 15 (30.0) | 2 (16.7) | |
| 0 | 3(10.0) | 0 | 0 | 0 | |
| 0 | 0 | 0 | 1 (2.0) | 1 (8.3) | |
| 1(6.7) | 0 | 0 | 0 | 0 | |
| Coliforms | 1(6.8) | 0 | 0 | 1 (2.0) | 0 |
| Coagulase negative staphylococcus | 0 | 0 | 2(6.9) | 1 (2.0) | 0 |
| Total | 15 (100.0) | 30 (100.0) | 29 (100.0) | 50 (100.0) | 12 (100.0) |
Antimicrobial susceptibility patterns of meningitis pathogens
| Penicillin | 98.9 (89/90) | 100.0 (3/3) | 0(0/1) | --- | -- | -- | 57.1 (4/7) |
| Chloramphenicol | 83.0 (73/88) | 100.0 (2/2) | 100.0 (1/1) | 25.0 (1/4) | -- | 66.7 (2/3) | 77.8 (7/9) |
| Ceftriaxone | 100.0 (86/86) | 100.0 (2/2) | 100.0 (1/1) | 100.0 (3/3) | 100.0 (2/2) | 100.0 (3/3) | 83.3 (5/6) |
| Cefotaxime | 100.0 (16/16) | 100.0 (2/2) | -- | 100.0 (3/3) | -- | 66.7 (2/3) | 50.0 (2/4) |
| Septrin | -- | -- | -- | 0 (0/4) | -- | 0 (0/3) | 14.3 (1/7) |
| Ampicillin | -- | -- | 0(0/1) | 0 (0/3) | -- | 0 (0/4) | 14.3 (1/7) |
| Gentamycin | -- | -- | -- | 100 (2/2) | 50 (1/2) | 50.0 (1/2) | 60.0 (3/5) |
| Ceftazidime | -- | -- | -- | 0 (0/1) | 0 (0/2) | -- | -- |
| Amikacin | -- | -- | -- | 100.0 (2/2) | 50 (1/2) | 100 (3/3) | 100.0 (3/3) |
Othersb: This represents the cumulative percentage of the following organisms: Klebsiella species, Enterobacter species, Staphylococcus aureus, Coagulase negative staphylococcus and Coliforms. Pseudomonas species includes Pseudomonas aeruginosa organisms. Antibiotics were not tested against all organisms with dash (--).
Figure 1Confirmed meningitis for all patients stratified by year. The figure describes the monthly distribution of all patients classified as having confirmed meningitis.